[Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients].
OBJECTIVE
In developed countries, where the mother-to-child transmission rate of HIV is low (1 to 1,5%), a major medical concern is the safety of new therapies during pregnancy. Teratogenicity has been described with an NNRTI, efavirenz (Sustiva), in animal model, regarding neural tube defects.


METHODS
We have made a retrospective study of pregnancies starting with efavirenz with a special focus on foetal and infant abnormalities.


RESULTS
Three abnormalities were notified no one linked to a neural tube defect.


CONCLUSIONS
In the English literature published, although the prevalence of abnormalities in human is low (1,7%) during pregnancy, due to the potent teratogenicity, efavirenz is contraindicated in the first trimester and should be used with caution in women of childbearing potential.
Jeantils
V
V
Service des maladies infectieuses, hôpital Jean-Verdier (AP-HP), Seine-Saint-Denis, avenue du 14-Juillet, 93140 Bondy, France. vincent.jeantils@jvr.aphp.fr
Khuong
M-A
MA
Delassus
J-L
JL
Honoré
P
P
Taverne
B
B
Uzan
M
M
Tassi
S
S
D000014:Abnormalities, Drug-Induced / Q000453:epidemiology*; D000480:Alkynes; D019380:Anti-HIV Agents / Q000009:adverse effects* / Q000627:therapeutic use; D048588:Benzoxazines; D003521:Cyclopropanes; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D010078:Oxazines / Q000009:adverse effects* / Q000627:therapeutic use; D011247:Pregnancy; D011251:Pregnancy Complications, Infectious / Q000188:drug therapy*; D012189:Retrospective Studies
D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; C098320:efavirenz